Absorption of Phenolic Acids From Coffee in Humans

Status Completed

Clinical Trial Summary

Phenolic acids are naturally-occurring constituents of plant-derived foods and beverages and are characterised by a phenol ring in their structure. The phenolic compounds we are going to focus on in this study are the Chlorogenic acids (CGAs), a family of esters conjugates formed between a Hydroxycinnamic acid and quinic acid (1) and that show a strong antioxidant activity (2).

HCAs represent about 50% of the total polyphenolic coumpounds intake in a typical UK diet (3) and for people who drink it, coffee is a/the major dietary source of/for HCAs (4). A few studies suggest protective effects for cardiovascular diseases (5), neurodegenerative diseases, type 2 diabetis and liver and kidneys cancer risk. However, many data in the field are obtained from in vitro and/or in animal, and it is difficult and dangerous to extrapolate between these and risk in humans of development or progression of particular health conditions, more human studies are therefore needed.

We aim to compare people that metabolise the best CGAs from coffee to those that metabolise them the least well. This will be achieved by measuring the metabolites in urine. The effect of CGAs on the human body does not only depend on the amount ingested, but also on the quality of the metabolism, we therefore also want to determine which mechanisms are responsible for inter-individual variations in order to identify any link with health biomarkers, these including non-cellular inflammation and cardiovascular risk indicators.

For this cohort study funded by the University of Leeds, approximately 60 healthy volunteers will be recruited at the School of Food Science & Nutrition. If they meet the selection criteria, participants will be asked to undergo a 36-hour wash-out period. During those 36 hours, participants won't be allowed to drink coffee, they will be asked to follow a diet low in phenolic acids and keep a record of their meals. On the first day of the study, a single dose of coffee rich in antioxidants will be given to the participant and urine will be collected from that time until 36 hours after coffee consumption. Participants will be followed again after 5 to 6 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01912144
Study type	Interventional
Source	University of Leeds
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2012
Completion date	June 27, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06043739` - Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects	Phase 1
Completed	`NCT02557139` - Bioavailability of Belumosudil (KD025) in Healthy Male Subjects	Phase 1
Completed	`NCT02010944` - A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels	Phase 1
Not yet recruiting	`NCT01136551` - Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A	N/A
Completed	`NCT01208155` - Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets	Phase 1
Completed	`NCT04097808` - Impact of the Source and Food Matrices on the Bioavailability of Peptan® (Collagen Peptides) in Healthy Subjects	N/A
Active, not recruiting	`NCT06098001` - Bioavailability Study of Hemp Phenolics	N/A
Completed	`NCT03915626` - Effect of Heat on Rivastigmine TDS Products	Early Phase 1
Completed	`NCT01448772` - Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions	Phase 1
Completed	`NCT01464450` - Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants	Phase 1
Completed	`NCT01181973` - Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects	Phase 1
Completed	`NCT00858767` - Arabic Gum-Absorption Study	N/A
Completed	`NCT04113564` - Absolute Oral Bioavailability of Remimazolam	Phase 1
Completed	`NCT04645394` - Bioavailability of Anthocyanins From Aronia Extract in Healthy Men - a Pilot Study	N/A
Completed	`NCT03485885` - Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects
Completed	`NCT05840848` - Effect of Iron and Zinc Supplementation on B-carotene Bioavailability in Healthy Males	N/A
Completed	`NCT02986529` - A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects	Phase 1
Completed	`NCT01789359` - Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding	N/A
Completed	`NCT01638143` - Bio-equivalence Study	N/A
Completed	`NCT00755872` - Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.